These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24187487)

  • 1. Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells.
    Cheng M; Xu H; Wang Y; Chen H; He B; Gao X; Li Y; Han J; Zhang Z
    Drug Des Devel Ther; 2013; 7():1287-99. PubMed ID: 24187487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
    Cheng M; Gao X; Wang Y; Chen H; He B; Xu H; Li Y; Han J; Zhang Z
    Mar Drugs; 2013 Sep; 11(9):3517-36. PubMed ID: 24048270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.
    Cheng M; Chen H; Wang Y; Xu H; He B; Han J; Zhang Z
    Int J Nanomedicine; 2014; 9():695-710. PubMed ID: 24493926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
    Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
    World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
    Cheng M; Ma D; Zhi K; Liu B; Zhu W
    Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies.
    Cheng M; Han J; Li Q; He B; Zha B; Wu J; Zhou R; Ye T; Wang W; Xu H; Hou Y
    J Biomed Mater Res B Appl Biomater; 2012 Nov; 100(8):2035-43. PubMed ID: 22865703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycyrrhetinic acid modified MOFs for the treatment of liver cancer.
    Li L; Han S; Yang C; Liu L; Zhao S; Wang X; Liu B; Pan H; Liu Y
    Nanotechnology; 2020 Aug; 31(32):325602. PubMed ID: 32320964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.
    Cheng M; Gao X; Wang Y; Chen H; He B; Li Y; Han J; Zhang Z
    Int J Nanomedicine; 2013; 8():4265-76. PubMed ID: 24232303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
    Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
    Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
    Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
    Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
    PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of chitosan-carboxymethyl dextran nanoparticles as a drug carrier and as a stimulator of mouse splenocytes.
    Lin YS; Radzi R; Morimoto M; Saimoto H; Okamoto Y; Minami S
    J Biomater Sci Polym Ed; 2012; 23(11):1401-20. PubMed ID: 21740648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting.
    Tian Q; Wang X; Wang W; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2010 Nov; 400(1-2):153-7. PubMed ID: 20813176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
    Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
    Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice.
    Zhang DY; Shen XZ; Wang JY; Dong L; Zheng YL; Wu LL
    World J Gastroenterol; 2008 Jun; 14(22):3554-62. PubMed ID: 18567086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of sequential combination of 5-fluorouracil-loaded-chitosan-nanoparticles and ALA-photodynamic therapy on HeLa cell line.
    Benito-Miguel M; Blanco MD; Gómez C
    Photodiagnosis Photodyn Ther; 2015 Sep; 12(3):466-75. PubMed ID: 25976508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronidase enzyme core-5-fluorouracil-loaded chitosan-PEG-gelatin polymer nanocomposites as targeted and controlled drug delivery vehicles.
    Rajan M; Raj V; Al-Arfaj AA; Murugan AM
    Int J Pharm; 2013 Sep; 453(2):514-22. PubMed ID: 23796828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytocompatible chitosan-graft-mPEG-based 5-fluorouracil-loaded polymeric nanoparticles for tumor-targeted drug delivery.
    Antoniraj MG; Ayyavu M; Henry LJK; Nageshwar Rao G; Natesan S; Sundar DS; Kandasamy R
    Drug Dev Ind Pharm; 2018 Mar; 44(3):365-376. PubMed ID: 28835136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing therapeutic efficacy: sustained delivery of 5-fluorouracil (5-FU) via thiolated chitosan nanoparticles targeting CD44 in triple-negative breast cancer.
    Anjum S; Naseer F; Ahmad T; Jahan F; Qadir H; Gul R; Kousar K; Sarwar A; Shabbir A
    Sci Rep; 2024 May; 14(1):11431. PubMed ID: 38763930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.